Department of Ophthalmology, Rabin Medical Center, Petah Tiqwa and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Curr Eye Res. 2010 Feb;35(2):108-15. doi: 10.3109/02713680903429007.
PURPOSE: This study sought to evaluate the efficacy of bevacizumab (Avastin), an anti-VEGF agent, in the reduction of corneal neovascularization in a rodent model, and compare between the effect of intraocular and subconjunctival injection. METHODS: Corneal neovascularization was induced by application of a mixture of 75% silver nitrate and 25% potassium nitrate to the corneal center of the right eye of 125 mice. Immediately thereafter, 75 eyes were treated with subconjunctival, anterior chamber, or intravitreal injection of bevacizumab. The remaining mice served as a control. The groups were compared at different postoperative time points for percentage area of neovascularization evaluated by digital photos, the presence of corneal stromal vascular endothelial cells studied by immunohistochemical staining, and VEGF levels measured by real-time PCR. RESULTS: In the untreated eyes, percentage area of neovascularization increased from 11.3 +/- 7% on day 2 to 20 +/- 8.9% on day 4, 47 +/- 25.4% on day 8, and 51 +/- 24.7% on day 10. The percentage area of neovascularization following subconjunctival injection was 7 +/- 2.9% on day 2, 15.7 +/- 6% on day 4, 32.2 +/- 15.2% on day 8, and 39.7 +/- 14.5% on day 10. The percentage area of neovascularization following anterior chamber injection was 14.4 +/- 3% on day 2, 16.5 +/- 6.3% on day 4, 26.3 +/- 6.5% on day 8, and 19.8 +/- 1.2% on day 10. The percentage area of neovascularization following intravitreal injection was 11 +/- 2.5% on day 2, 14.7 +/- 5% on day 4, 23.5 +/- 6.5% on day 8, and 24.2 +/- 14.9% on day 10. CONCLUSIONS: Bevacizumab injections partially inhibit the growth of corneal neovascularization induced by acute chemical injury in a mouse model. The intraocular routes of injection were found to be the most effective, and the subconjunctival route of injection yielded the earliest peak response.
目的：本研究旨在评估抗血管内皮生长因子（VEGF）药物贝伐单抗（Avastin）在减少鼠角膜新生血管形成方面的疗效，并比较玻璃体内、前房内和球结膜下注射的效果。
方法：将 75%硝酸银和 25%硝酸钾混合物应用于 125 只小鼠右眼中央角膜，诱导角膜新生血管形成。此后，75 只眼立即接受贝伐单抗球结膜下、前房内或玻璃体内注射。其余小鼠作为对照。在不同的术后时间点，通过数码照片评估新生血管面积百分比、免疫组化染色检测角膜基质血管内皮细胞、实时 PCR 检测 VEGF 水平，对各组进行比较。
结果：未治疗组眼，新生血管面积百分比从第 2 天的 11.3%±7%增加到第 4 天的 20%±8.9%、第 8 天的 47%±25.4%和第 10 天的 51%±24.7%。球结膜下注射后第 2 天新生血管面积百分比为 7%±2.9%，第 4 天为 15.7%±6%，第 8 天为 32.2%±15.2%，第 10 天为 39.7%±14.5%。前房内注射后第 2 天新生血管面积百分比为 14.4%±3%，第 4 天为 16.5%±6.3%，第 8 天为 26.3%±6.5%，第 10 天为 19.8%±1.2%。玻璃体内注射后第 2 天新生血管面积百分比为 11%±2.5%，第 4 天为 14.7%±5%，第 8 天为 23.5%±6.5%，第 10 天为 24.2%±14.9%。
结论：贝伐单抗注射部分抑制了鼠角膜急性化学损伤诱导的新生血管生长。眼内注射途径最有效，球结膜下注射途径起效最快。
Invest Ophthalmol Vis Sci. 2009-4
Am J Ophthalmol. 2008-3
Ophthalmic Res. 2012-4-24
Front Med (Lausanne). 2020-11-10
J Control Release. 2020-11-10
Invest Ophthalmol Vis Sci. 2019-1-2
Eye Vis (Lond). 2017-12-10
Signal Transduct Target Ther. 2016
J Med Life. 2015
Zotero 插件